129 related articles for article (PubMed ID: 35866838)
1. Health economic evaluation of an mRNA high-risk human papillomavirus (HR-HPV) assay versus a DNA HR-HPV assay for the proposed French cervical screening programme.
Dombrowski CA; Weston GM; Descamps PP; Izopet PJ; Adams EJ; Adams E
Medicine (Baltimore); 2022 Jul; 101(29):e29530. PubMed ID: 35866838
[TBL] [Abstract][Full Text] [Related]
2. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation.
Weston G; Dombrowski C; Harvey MJ; Iftner T; Kyrgiou M; Founta C; Adams EJ
BMJ Open; 2020 Mar; 10(3):e031303. PubMed ID: 32152154
[TBL] [Abstract][Full Text] [Related]
3. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared to HR-HPV and liquid-based cytology co-testing.
Dombrowski C; Bourgain C; Ma Y; Meiwald A; Pinsent A; Weynand B; Turner KME; Huntington S; Adams EJ; Bogers J; Croes R; Sahebali S
Eur J Cancer Prev; 2024 May; 33(3):262-270. PubMed ID: 37933867
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
8. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
[TBL] [Abstract][Full Text] [Related]
9. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
Barré S; Massetti M; Leleu H; De Bels F
BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility and budget impact analyses of cervical cancer screening using self-collected samples for HPV DNA testing in Thailand.
Kositamongkol C; Kanchanasurakit S; Mepramoon E; Talungchit P; Chaopotong P; Kengkla K; Chaisathaphol T; Saokaew S; Phisalprapa P
BMC Public Health; 2023 Dec; 23(1):2413. PubMed ID: 38049773
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Performance of HPV E6/E7 mRNA and HPV DNA Assays for the Detection and Screening of Oncogenic Human Papillomavirus Infection among Woman with Cervical Lesions in China.
Wang HY; Lee D; Park S; Kim G; Kim S; Han L; Yubo R; Li Y; Park KH; Lee H
Asian Pac J Cancer Prev; 2015; 16(17):7633-40. PubMed ID: 26625774
[TBL] [Abstract][Full Text] [Related]
12. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
13. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
14. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
15. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
17. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain.
Ibáñez R; Mareque M; Granados R; Andía D; García-Rojo M; Quílez JC; Oyagüez I
BMC Womens Health; 2021 Apr; 21(1):178. PubMed ID: 33902553
[TBL] [Abstract][Full Text] [Related]
19. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.
Skroumpelos A; Agorastos T; Constantinidis T; Chatzistamatiou K; Kyriopoulos J
PLoS One; 2019; 14(12):e0226335. PubMed ID: 31830114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
